In vitro activity of linezolid, synercid and telithromycin against genetically defined high level fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus.
The in vitro activity of levofloxacin, moxifloxacin, gatifloxacin, erythromycin, telithromycin, linezolid, synercid and vancomycin was measured against 36 genetically defined, gyrA/grlA double mutant MRSA clinical strains with an MIC to ciprofloxacin > or = 8 mg/l. The three newer fluoroquinolones tested were more active than ciprofloxacin. Resistance rates for levofloxacin and gatifloxacin were high (44.5 and 36.1%, respectively). All the strains were moxifloxacin-susceptible, though most of them had MICs close to the break point. All the strains were intermediate or resistant to erythromycin and most were also resistant to telithromycin. No strains were resistant to linezolid, synercid or vancomycin (MIC(90): 2, 1 and 2 mg/l, respectively).
Muñoz Bellido
J L
JL
Departamento de Medicina Preventiva, Salud Pública y Microbiología Médica, Universidad de Salamanca, Salamanca, Spain.
Gutiérrez Zufiaurre
M N
MN
Sánchez Hernández
F J
FJ
Yagüe Guirao
G
G
Segovia Hernández
M
M
García-Rodríguez
J A
JA
D000081:Acetamides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D018432:Drug Resistance, Multiple; D066298:In Vitro Techniques; D048628:Ketolides; D000069349:Linezolid; D018942:Macrolides; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000494:pharmacology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D014640:Vancomycin / Q000494:pharmacology; D014769:Virginiamycin / Q000494:pharmacology
D000081:Acetamides; D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; D023303:Oxazolidinones; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D014640:Vancomycin; D000069349:Linezolid; C106791:telithromycin